Insights from CTTACC: immune system reset by cellular therapies for chronic illness after trauma, infection, and burn

IF 3.7 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Cytotherapy Pub Date : 2024-07-01 DOI:10.1016/j.jcyt.2024.02.013

Kenneth Bertram , Charles Cox , Hasan Alam , Clifford Lowell , Joseph Cuschieri , Biju Parekkadan , Shibani Pati

{"title":"Insights from CTTACC: immune system reset by cellular therapies for chronic illness after trauma, infection, and burn","authors":"Kenneth Bertram , Charles Cox , Hasan Alam , Clifford Lowell , Joseph Cuschieri , Biju Parekkadan , Shibani Pati","doi":"10.1016/j.jcyt.2024.02.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Background Aims</h3><p>In this paper, we present a review of several selected talks presented at the CTTACC conference (Cellular Therapies in Trauma and Critical Care) held in Scottsdale, AZ in May 2023. This conference review highlights the potential for cellular therapies to “reset” the dysregulated immune response and restore physiologic functions to normal. Improvements in medical care systems and technology have increasingly saved lives after major traumatic events. However, many of these patients have complicated post-traumatic sequelae, ranging from short-term multi-organ failure to chronic critical illness.</p></div><div><h3>Methods/Results</h3><p>Patients with chronic critical illness have been found to have dysregulated immune responses. These abnormal and harmful immune responses persist for years after the initial insult and can potentially be mitigated by treatment with cellular therapies.</p></div><div><h3>Conclusions</h3><p>The sessions emphasized the need for more research and clinical trials with cellular therapies for the treatment of a multitude of chronic illnesses: post-trauma, radiation injury, COVID-19, burns, traumatic brain injury (TBI) and other chronic infections.</p></div>","PeriodicalId":50597,"journal":{"name":"Cytotherapy","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1465324924000598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background Aims

In this paper, we present a review of several selected talks presented at the CTTACC conference (Cellular Therapies in Trauma and Critical Care) held in Scottsdale, AZ in May 2023. This conference review highlights the potential for cellular therapies to “reset” the dysregulated immune response and restore physiologic functions to normal. Improvements in medical care systems and technology have increasingly saved lives after major traumatic events. However, many of these patients have complicated post-traumatic sequelae, ranging from short-term multi-organ failure to chronic critical illness.

Methods/Results

Patients with chronic critical illness have been found to have dysregulated immune responses. These abnormal and harmful immune responses persist for years after the initial insult and can potentially be mitigated by treatment with cellular therapies.

Conclusions

The sessions emphasized the need for more research and clinical trials with cellular therapies for the treatment of a multitude of chronic illnesses: post-trauma, radiation injury, COVID-19, burns, traumatic brain injury (TBI) and other chronic infections.

查看原文本刊更多论文

来自 CTTACC 的启示：通过细胞疗法重置免疫系统，治疗创伤、感染和烧伤后的慢性疾病。

在本文中，我们将对 2023 年 5 月在亚利桑那州斯科茨代尔举行的 CTTACC 会议（创伤和重症监护中的细胞疗法）上发表的几篇精选演讲进行综述。本会议综述强调了细胞疗法在 "重置 "失调免疫反应和恢复正常生理功能方面的潜力。医疗保健系统和技术的改进越来越多地挽救了重大创伤事件后的生命。然而，许多患者都有复杂的创伤后遗症，从短期的多器官功能衰竭到慢性危重病。研究发现，慢性危重症患者的免疫反应失调。这些异常和有害的免疫反应在最初的损伤后持续数年，有可能通过细胞疗法得到缓解。会议强调，需要对细胞疗法治疗多种慢性疾病进行更多的研究和临床试验：创伤后、辐射损伤、COVID-19 和其他慢性感染、烧伤和脑外伤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytotherapy 医学-生物工程与应用微生物

CiteScore

6.30

自引率

4.40%

发文量

683

审稿时长

49 days

期刊介绍： The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.